Menopause before 40: premature ovarian insufficiency
Before 40, periods that disappear or go haywire are not just stress, and you are too young for that is not a diagnosis. This video first puts the right words on it: premature ovarian insufficiency before 40 is not the same thing as early menopause between 40 and 45, and it is not always permanent. It explains what should trigger testing (four months of absent or clearly irregular periods before 40) and the dosing rule that changed: the 2024 international recommendation, co-signed by the European, American and international societies, now accepts a single FSH measurement above 25 IU/l. It reviews the causes (genetic including the FMR1 gene, autoimmune, iatrogenic after a cancer treated in childhood), the reasonable workup to ask for, and what the literature documents for bone and heart, with absolute risk and not only relative risk. The heart of the topic is an inversion of the hormonal reasoning: at fifty-two, taking hormone therapy means adding something to a body that stopped producing it at the age when that is normal; at thirty-five, not taking it means letting a thirty-five-year-old body run without what it should have. It is no longer a comfort treatment, it is a replacement, and the guidelines say to continue it at least until the usual age of menopause. The video finally addresses fertility without promises and without fatalism, and the shock of the diagnosis, which is part of the picture and not beside it. In French with English subtitles.
Watch on YouTube (full description and references) →
Read the written and sourced version of this topic →
What you will understand
Before 40, periods that space out, disappear, then come twice in the month (sometimes with waking up in sweat and hot flashes in the middle of the day), that is not "stress". Many women are told they are too young for that. That sentence is not a diagnosis.
Vocabulary matters, because it is misused everywhere. When the ovaries stop working normally before 40, we speak of premature ovarian insufficiency, and not of menopause, precisely because it is not always permanent. When the stop occurs between 40 and 45, we speak of early menopause. The figures in circulation constantly mix these two situations: the Golezar meta-analysis (PMID 30829083) gives 3.7% for premature ovarian insufficiency and 12.2% for menopause before 45, which does not describe the same number of women at all.
The trigger for testing is simple and worth knowing: under 40, and periods absent or clearly irregular for at least four months. FSH is then measured. On this point, the rule has recently changed: the 2024 international recommendation, co-signed by the European, American and international societies (PMID 39660328), now holds that a single measurement above 25 IU/l is enough, where two measurements four weeks apart were previously required. AMH is not the first-line criterion: it comes in when the picture remains doubtful.
In about half of cases, no cause is found. When one is found, it is genetic (sex chromosome abnormalities, a particularity of the FMR1 gene, found in 1.9% of 1,095 women with collapsed ovarian reserve, PMID 37987117), autoimmune (10.2% of the 461 women in the Norwegian Addison's disease registry also had premature ovarian insufficiency, PMID 33686417), or iatrogenic. This last point is very concrete: in the Childhood Cancer Survivor Study, 8% of the 2,819 survivors of a childhood cancer had had a non-surgical early menopause, versus 0.8% of their sisters (PMID 16818852).
In the long term, two organs are concerned. Bone first, with the most solid data: among 8,603 Australian women followed for 23 years, the 610 who had menopause before 45 had a fracture risk increased by about 45%, and among those who already had osteoporosis or a fracture, fewer than four in ten had ever received a bone treatment (PMID 38396142). The heart next: in the UK Biobank, among 144,260 women, the risk of a cardiovascular event was increased by about 36% in case of natural menopause before 40, which represents in absolute terms a move from about 5.7 to 8.8 events per 1,000 women per year (PMID 31738818). These are observational data: they show an association, not a demonstrated mechanism.
That is what makes the hormonal reasoning the reverse of the one we know. At 52, taking hormone therapy means adding something to a body that stopped producing it at the age when that is normal: a shared decision. At 35, not taking it means letting a 35-year-old body run without what it should have: the comparator is not a treated 52-year-old woman, but a woman of the same age whose ovaries are working. The American college of gynecologists writes it in black and white: treatment should be continued at least until the average age of natural menopause, around 50 to 51 (PMID 28426619). In practice, among 310,404 Swedish women aged 40 to 44, fewer than one in a hundred had started one (PMID 25662809).
The key points to remember
- "You are too young for that" is not a diagnosis. Before 40, four months of absent or clearly irregular periods justify an FSH measurement.
- Premature ovarian insufficiency (before 40) and early menopause (40 to 45) do not mean the same thing. The figures in circulation constantly confuse the two.
- It is not always permanent: in some women, ovarian activity resumes intermittently for years.
- Since 2024, a single FSH measurement above 25 IU/l is enough for the diagnosis, versus two previously. AMH is not the first-line criterion.
- In about half of cases, no cause is found, which does not mean no one looked.
- The reasonable workup includes a karyotype, testing for a particularity of the FMR1 gene, adrenal antibodies, a TSH measurement and a bone density scan.
- Bone is the best documented risk, and the least treated: among the women concerned who already had osteoporosis or a fracture, fewer than four in ten had received a treatment.
- Cardiovascular risk is increased, but you must read the absolute risk as much as the relative risk: about 5.7 to 8.8 events per 1,000 women per year.
- At this age, hormone therapy is not a comfort treatment but a replacement, to be continued at least until the usual age of menopause. It remains a shared medical decision.
- Premature ovarian insufficiency is not contraception: about 4% of spontaneous pregnancies are documented. And no treatment has shown that it increases those chances.
Frequently asked questions
At what point should you worry about irregular periods before 40?
The marker is simple: periods absent or clearly irregular for at least four months, before 40, justify a blood FSH measurement. This is not a situation to be monitored indefinitely while telling yourself it will settle down. If the result is high, the diagnosis can be made, and it opens management that has concrete consequences for bone, heart and fertility.
Is it really the same thing as menopause?
No, and that is why specialists have abandoned the word menopause in this context. A menopause is permanent. Premature ovarian insufficiency is not always: there are women in whom the ovary switches back on intermittently for years. In a French series of 358 patients, nearly one in four showed signs of resumed ovarian activity (PMID 21994953).
Can you still have a child?
The two extreme answers are both wrong. It is not definitively over: in the same series of 358 women, 21 spontaneous pregnancies occurred in 15 patients, that is, a little more than 4%. But it is not a promise either: a systematic review of the treatments proposed to restore ovarian function is categorical, none has shown that it increases those chances (PMID 10582785). So be wary of anything that promises the opposite, especially if it is paid for. Egg donation is a path to discuss with a specialized team.
Do you still need contraception?
That is a question to ask your doctor explicitly. Premature ovarian insufficiency is not contraception: spontaneous pregnancies do occur. The American college of gynecologists also points out that combined hormonal contraception prevents pregnancy more reliably than hormone replacement therapy, which is a real trade-off for those who do not want a pregnancy.
Is hormone therapy not dangerous, after what we have read about hormones?
The fear of hormones comes from a large 2002 study conducted in women who reached menopause at the usual age, on average around 63 at inclusion. It says nothing about the situation of a 35-year-old woman. At that age, the treatment is not added to a body that has normally stopped producing: it replaces what the body should be producing. The recommendations call for continuing it at least until the average age of natural menopause. It remains a shared medical decision: the route and the dose are discussed with a doctor.
Is hormone therapy preferable to the pill for bone?
The data lean that way, but they are scarce and that must be said honestly. A randomized trial showed a greater gain in bone density at the lumbar spine with hormone therapy, but in 59 women included, of whom only 36 completed (PMID 27340881), and a systematic review of all available studies does not find this result consistently (PMID 35213521). What is solid, on the other hand, is that in the group taking nothing, bone density fell at every site.
How is the diagnosis made?
On a set of elements, never on a single blood test. The doctor relies on age, on periods that have been absent or very irregular for several months, and on hormonal measurements repeated a few weeks apart, because an isolated result can mislead. A complementary workup is often proposed to look for a cause. This approach belongs to the doctor who follows you.
Why does this situation require long-term follow-up?
Because the hormonal deficiency starts much earlier than in a menopause occurring at the usual age, and therefore lasts longer. Bone and the cardiovascular system are the two areas that justify particular attention, with psychological support when the announcement is brutal. The terms and duration of management are decided with the medical team, depending on your situation.